Search results for "Staging system"

showing 5 items of 25 documents

The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1

2016

International Liver Cancer Association Congress 2015, Paris, France, 4–6 September 2015 Since its creation 9 years ago, in 2007, the International Liver Cancer Association has focused on the multidisciplinary approach to liver cancer due to advances in hepatology science and care worldwide. In its 2015 annual conference, held on 4–6 September in Paris, France, the most recent progresses in the basic biology, management and treatment of liver cancer have been presented. This report, divided into two parts, introduces and critically reviews some of the most intriguing topics discussed at the meeting.

SorafenibCancer Researchmedicine.medical_specialtysurvivalliver cancer03 medical and health sciences0302 clinical medicineInternal medicinestaging systemmedicineHumansHCCDisease management (health)Staging systembusiness.industryCarcinomaLiver NeoplasmsDisease ManagementHCC; immunotherapy; liver cancer; prognosis; sorafenib; staging system; survival; trial design; Carcinoma Hepatocellular; Disease Management; Humans; Liver Neoplasms; Oncology; Cancer ResearchHepatocellularGeneral MedicineHepatologymedicine.diseaseOncology030220 oncology & carcinogenesisFamily medicinetrial designsorafenib030211 gastroenterology & hepatologyimmunotherapyprognosisLiver cancerbusinessmedicine.drugFuture Oncology
researchProduct

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction

2020

Right ventricular dysfunction (RVD) parameters are increasingly important features in heart failure with preserved ejection fraction (HFpEF). We sought to evaluate the prognostic impact of a progressive RVD staging system by combining the tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (TAPSE/PASP) ratio with functional tricuspid regurgitation (TR) severity. We prospectively included 1355 consecutive HFpEF patients discharged for acute heart failure (HF). Of them, in 471 (34.7%) patients, PASP could not be accurately measured, leaving the final sample size to be 884 patients. Patients were categorized as Stage 1: TAPSE/PASP &ge

heart failure with preserved ejection fractionmedicine.medical_specialtylcsh:Medicinerisk stratification030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arterymedicine030212 general & internal medicineStage (cooking)right ventricularStaging systemRisk stratificationRight ventricularbusiness.industryMortality ratelcsh:RGeneral Medicinemedicine.diseaseBlood pressureHeart failure with preserved ejection fractionHeart failurePulmonary arteryRisk stratificationCardiologybusinessHeart failure with preserved ejection fraction
researchProduct

Conservative Surgical Management of Stage I Bisphosphonate-Related Osteonecrosis of the Jaw

2014

Purpose. To report the efficacy of conservative surgical treatment for stage I bisphosphonate-related osteonecrosis of the jaw (BRONJ).Materials and Methods. This study reports the clinical outcomes of 63 patients treated for BRONJ stage I (according to Ruggiero's staging system) at the Oral Pathology and Laser-Assisted Surgery Unit of the University of Parma between January 2004 and January 2011. Surgical interventions were performed, under local analgesia, in patients unresponsive for a period of six months to noninvasive treatments such as cycles of local or systemic antibacterial therapy combined or not to low level laser therapy, ozone therapy, or Hyperbaric Oxygen Therapy. All interve…

medicine.medical_specialtyArticle Subjectbusiness.industrymedicine.medical_treatmentDiseaseBisphosphonatemedicine.diseaseOzone therapySurgerylcsh:RK1-715lcsh:DentistryOral and maxillofacial pathologymedicineClinical StudyIn patientbusinessOsteonecrosis of the jawGeneral DentistryStaging systemLow level laser therapyInternational Journal of Dentistry
researchProduct

Monofocal hepatocellular carcinoma: How much does size matter?

2020

Background & Aims: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, monofocal hepatocellular carcinoma (HCC) is classified as early (BCLC A) irrespective of its size, even though controversies still exist regarding staging and treatment of large tumours. We aimed at evaluating the appropriate staging and treatment for large (>5 cm) monofocal (HCC). Methods: From the Italian Liver Cancer database, we selected 924 patients with small early monofocal HCC (2-5 cm; SEM-HCC), 163 patients with larger tumours (>5 cm; LEM-HCC) and 1048 intermediate stage patients (BCLC B). Results: LEM-HCC patients had a worse overall survival (OS) than SEM-HCC (31.0 vs 49.0 months; P…

medicine.medical_specialtyMultivariate analysisCarcinoma HepatocellularIndependent predictorGastroenterologyResection03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalHepatectomyHumansStaging systemNeoplasm StagingRetrospective StudiesSettore MED/12 - GastroenterologiaHepatologytreatmentbusiness.industrySettore MED/09 - MEDICINA INTERNALiver Neoplasmsbclc staging systemmonofocal hepatocellular carcinomamedicine.diseasedigestive system diseasesSurvival benefitItaly030220 oncology & carcinogenesisHepatocellular carcinomabclc staging system; liver resection; monofocal hepatocellular carcinoma; prognosis; treatmentliver resection030211 gastroenterology & hepatologyprognosisbusinessLiver cancerprognosi
researchProduct

Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide

2021

Abstract Treatment of hepatocellular carcinoma (HCC) depends on the stage of disease. In the Western Hemisphere, the Barcelona Clinic Liver Cancer classification (BCLC) is the preferred staging system. Approximately one-third of patients initially present with intermediate-stage disease. For these patients, transarterial chemoembolization (TACE) is the treatment of choice. However, the intermediate-stage comprises a heterogeneous subgroup of patients with considerable differences in tumor burden and liver function. In addition, differences in individual factors that are not captured by the BCLC framework, such as the tumor growth pattern, degree of hypervascularity, and vascular supply, com…

medicine.medical_specialtybusiness.industrypractical step-by-step guideReviewhepatocellular carcinomatransarterial chemoembolizationHypervascularityDiseasemedicine.disease03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisHepatocellular carcinomaMedicine030211 gastroenterology & hepatologyTumor growthLiver functiontreatment decision supportStage (cooking)businessLiver cancerIntensive care medicinesurvival predictionStaging systemJournal of Hepatocellular Carcinoma
researchProduct